Ipamorelin peptide: the popular claims are larger than the human evidence.
Ipamorelin is a real pentapeptide with human pharmacology and Phase 2 records. That does not make the familiar muscle, fat-loss, recovery, sleep, anti-aging, blend, or dosage claims proven. This guide puts each claim beside the exact study and regulatory boundary.
Mechanism is not a list of proven benefits.
Ipamorelin can activate the ghrelin receptor and stimulate growth-hormone release. The cited human pharmacology study measured that short-term response after intravenous infusion. It did not test a commercial injection, muscle gain, fat loss, recovery, sleep, longevity, or a CJC-1295 blend.
The published randomized Phase 2 postoperative-ileus study enrolled 117 people and reported no significant difference in its key or secondary efficacy analyses. FDA's detailed review also identifies major characterization and route-specific safety gaps.
Read the Ipamorelin record in four fields.
This is a sourced status snapshot, not a safety score, treatment recommendation, or seller certification. Each field links back to the detailed record below.
2 Phase 2 records
The published 117-person trial was negative, while a 320-person registry has no posted results.
Inspect the human evidenceWellness benefits not proven
Hormone release does not establish muscle, fat-loss, sleep, recovery, or anti-aging outcomes.
Audit the popular claimsNo FDA-approved product
FDA says neither ipamorelin free base nor acetate is part of an approved drug.
Check status and destination routesDated US price boards
Identity, human study, and regulatory status answer different questions.
Keeping the lanes separate prevents a receptor mechanism, research listing, clinic claim, and approved drug from being presented as one thing.
A five-amino-acid ghrelin-receptor agonist
PubChem identifies ipamorelin as a pentapeptide, also searched as NNC 26-0161, with formula C38H49N9O5 and a listed molecular weight of 711.9 g/mol. Identity and receptor activity do not establish an approved indication or consumer benefit.
Short-term hormone response and two Phase 2 records
An early intravenous dose-escalation study measured pharmacokinetics and growth-hormone release. The two ClinicalTrials.gov intervention records studied postoperative gastrointestinal recovery, not muscle gain, fat loss, anti-aging, sleep, or athletic recovery.
Not a component of an FDA-approved drug
FDA's detailed review says neither ipamorelin free base nor ipamorelin acetate is a component of an FDA-approved drug. FDA also describes characterization, immunogenicity, impurity, and route-specific safety concerns for compounding.
Two records. Neither studies online wellness claims.
Checked July 20, 2026. Registry status, enrollment, intervention, posted results, and published findings are separate fields.
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
- Phase
- Phase 2
- Enrollment
- 117
Published randomized study found no statistically significant difference in its key or secondary efficacy analyses.
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
- Phase
- Phase 2
- Enrollment
- 320
The registry record has no posted results in the July 20, 2026 snapshot. Completion alone is not a positive result.
What the record shows, and what it cannot prove.
The “limit” column belongs beside every result. Removing it changes an observation into a marketing claim.
Growth-hormone release
Observed after intravenous infusion in a small 1999 dose-escalation study of healthy male volunteers.
A transient laboratory response is not proof of muscle gain, fat loss, recovery, sleep improvement, or long-term benefit.
Postoperative gastrointestinal recovery
Tested in completed Phase 2 records. The published 117-person randomized trial did not show significant efficacy differences.
This hospital research question does not validate wellness, bodybuilding, anti-aging, or subcutaneous-clinic claims.
Fewer side effects
No reliable current source establishes ipamorelin as the low-side-effect option against CJC-1295, sermorelin, growth hormone, or another secretagogue.
Separate studies, routes, doses, formulations, populations, and reporting methods cannot create a fair safety ranking.
CJC-1295 plus ipamorelin blend
The exact combination appears widely in seller and clinic pages, but neither ClinicalTrials.gov ipamorelin record is a CJC-1295 blend study.
Placing two names on one label does not create human evidence for the blend, a dosing protocol, compatibility, sterility, benefit, or safety.
Ipamorelin, CJC-1295, and sermorelin are three records.
Searches place them together. Identity and evidence do not.
Ipamorelin
A five-amino-acid growth-hormone secretagogue. The human records cited here use intravenous administration and do not establish an approved subcutaneous product.
Open ipamorelin record →CJC-1295 no-DAC
A distinct seller-labelled research identity. Shared growth-signaling language and blend marketing do not make it ipamorelin or supply combination evidence.
Resolve DAC, no-DAC, and human evidence →Compare the research-market records →Sermorelin
A longer, distinct peptide identity also searched as GHRH 1-29. This guide cites no head-to-head trial that proves it is better, safer, or interchangeable with ipamorelin.
Open sermorelin record →A US peptide page cannot decide another country's product status.
Peptide Local links the same ipamorelin identity to destination-specific medicine, pharmacy, seller, and supply records. Health Canada explicitly names ipamorelin among unauthorized injectable peptide examples and tells consumers to verify an eight-digit Drug Identification Number.
Eight questions, with the missing evidence kept visible.
This is educational reporting, not medical advice, a prescription, or an injection protocol.
What is ipamorelin peptide?
Ipamorelin is a synthetic five-amino-acid peptide and ghrelin-receptor agonist also identified as NNC 26-0161. Early human research showed that intravenous administration could stimulate a short-lived growth-hormone response. That mechanism does not establish an approved indication, pharmacy product, muscle-building outcome, fat-loss result, recovery benefit, or anti-aging effect.
What are the proven benefits of ipamorelin?
The cited human evidence does not prove the broad benefits promoted online. A small pharmacology study measured growth-hormone release, and the published randomized Phase 2 postoperative-ileus trial did not find significant differences in the key or secondary efficacy analyses. Neither record tested the common online claims for body composition, athletic recovery, sleep, or longevity.
What side effects were reported with ipamorelin?
The published 117-person Phase 2 article reported high overall treatment-emergent adverse-event rates in both the ipamorelin and placebo groups. FDA's broader review discusses hypokalemia, insomnia, hyperglycemia, nausea, vomiting, abdominal distention, and two deaths in an intravenous postoperative study, while stating that it was unclear whether the deaths were related to ipamorelin. These observations do not define a routine side-effect rate for a different route or product.
Is ipamorelin FDA approved?
No FDA-approved ipamorelin product is established by the cited FDA record. FDA's 2024 briefing says neither the free base nor acetate is a component of an FDA-approved drug. The agency proposed against adding both to the 503A Bulks List and separately lists potential significant safety risks for compounded ipamorelin acetate. A proposal, interim category, seller listing, or substance identifier must not be rewritten as an approved drug label.
What is the correct ipamorelin dosage?
There is no FDA-approved ipamorelin dosage for the online research or wellness products discussed here. Intravenous research regimens from hospital or pharmacology studies cannot be converted into a subcutaneous self-use protocol. This guide does not reproduce dosing, reconstitution, stacking, or injection instructions for an unapproved product.
Is CJC-1295 with ipamorelin supported by a human trial?
Not by the two ClinicalTrials.gov ipamorelin intervention records in this dated review. Both records concern postoperative gastrointestinal recovery and neither lists a CJC-1295 combination. Ipamorelin and CJC-1295 no-DAC also have distinct molecular identities and research-price board sizes on Peptide Local. A blend listing is not clinical evidence.
Ipamorelin vs sermorelin: are they the same?
No. Ipamorelin is a ghrelin-receptor agonist and growth-hormone secretagogue. Sermorelin is a synthetic growth hormone-releasing hormone fragment. Their identities, receptor pathways, molecule sizes, historical records, research listings, and evidence are different. There is no head-to-head trial cited here that names a winner for benefit or safety.
Can you buy ipamorelin in another country?
A search result or shipping claim cannot answer that. Product authorization, compounding rules, prescription status, pharmacy licensing, import controls, seller identity, and the exact formulation vary by destination. Health Canada specifically names ipamorelin among unauthorized injectable peptide examples. Use the country map and official local records before interpreting any offer.
No approved dosage or blend protocol is hidden in an intravenous study.
Route, formulation, purity, aggregation, sterility, dose, patient population, endpoints, and monitoring all matter. FDA states that important safety information is missing for certain injectable routes and that the proposed subcutaneous effectiveness evidence was insufficient.
A seller's “research only” vial, a compounded preparation, and a sponsor-controlled clinical-trial product are not interchangeable evidence lanes. A price or certificate cannot establish medical suitability.